-
Cancer Chemotherapy and Biological... 1987
Review
Topics: Animals; Cell Survival; Humans; Mitomycin; Mitomycins
PubMed: 3152789
DOI: No ID Found -
FEMS Microbiology Ecology May 2023A viral shunt can occur when phages going through a lytic cycle, including lysogenic phages triggered by inducing agents (e.g. mitomycin C), results in host lysis and...
A viral shunt can occur when phages going through a lytic cycle, including lysogenic phages triggered by inducing agents (e.g. mitomycin C), results in host lysis and the release of cell constituents and virions. The impact of a viral shunt on the carbon, including methane cycle in soil systems is poorly understood. Here, we determined the effects of mitomycin C on the aerobic methanotrophs in a landfill cover soil. To an extent, our results support a mitomycin C-induced viral shunt, as indicated by the significantly higher viral-like particle (VLP) counts relative to bacteria, elevated nutrient concentrations (ammonium, succinate), and initially impaired microbial activities (methane uptake and microbial respiration) after mitomycin C addition. The trend in microbial activities at <2 days largely corresponded to the expression of the pmoA and 16S rRNA genes. Thereafter (>11 days), the active bacterial community composition significantly diverged in the mitomycin C-supplemented incubations, suggesting the differential impact of mitomycin C on the bacterial community. Collectively, we provide insight on the effects of mitomycin C, and potentially a viral shunt, on the bacteria in the soil environment.
Topics: Oxidation-Reduction; Mitomycin; Soil; RNA, Ribosomal, 16S; Bacteria; Waste Disposal Facilities; Methane; Soil Microbiology
PubMed: 37156510
DOI: 10.1093/femsec/fiad047 -
Cancer Treatment Reviews Dec 1985
Review
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Mitomycin; Mitomycins
PubMed: 3938680
DOI: 10.1016/0305-7372(85)90007-6 -
Methods in Enzymology 2004
Review
Topics: Animals; Antibiotics, Antineoplastic; Bacterial Proteins; Biotransformation; Drug Resistance, Neoplasm; Humans; Mitomycin; Oxidation-Reduction; Oxidoreductases
PubMed: 15047104
DOI: 10.1016/S0076-6879(04)82012-3 -
The Medical Journal of Australia Sep 1989
Topics: Carcinoma, Squamous Cell; Female; Heart Failure; Humans; Middle Aged; Mitomycin; Mitomycins; Uterine Cervical Neoplasms
PubMed: 2505026
DOI: 10.5694/j.1326-5377.1989.tb101205.x -
Seminars in Oncology Jun 1988Mitomycin C is a chemotherapeutic agent active against breast cancer. Because one of its potential toxicities is prolonged myelosuppression, it is not generally used in... (Review)
Review
Mitomycin C is a chemotherapeutic agent active against breast cancer. Because one of its potential toxicities is prolonged myelosuppression, it is not generally used in first-line chemotherapy regimens. However, several mitomycin C-containing combinations are effective in the salvage therapy of patients that have failed to respond to previous regimens. The choice of a salvage combination depends on the previous treatment received by an individual patient. Patients failing regimens based on CMF (cyclophosphamide, methotrexate, 5-fluorouracil [5-FU]) should be treated with combinations incorporating drugs not included in CMF. Active agents in this setting include mitomycin C, doxorubicin, and vinca alkaloids (usually vinblastine). Patients treated with combinations based on doxorubicin and cyclophosphamide (AC) are frequently administered a CMF-type regimen after a cumulative dose of doxorubicin has been reached. Therefore, they have often received doxorubicin, cyclophosphamide, methotrexate, and 5-FU. Salvage chemotherapy for failing patients in this setting is generally based on mitomycin C and/or vinblastine. Selection of a chemotherapeutic regimen for breast cancer must take into account the palliative nature of chemotherapy in this disease. Consequently, effective combinations that can be administered with minimal disruption of a patient's life-style are preferred.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mitomycin; Mitomycins
PubMed: 3134698
DOI: No ID Found -
Journal of Glaucoma Jul 2019The use of mitomycin-C as a mixed formulation with lidocaine and epinephrine for filtration surgery may alter its pH and consequently affect clinical effectivity.
The use of mitomycin-C as a mixed formulation with lidocaine and epinephrine for filtration surgery may alter its pH and consequently affect clinical effectivity.
Topics: Chemistry, Pharmaceutical; Combined Modality Therapy; Drug Compounding; Filtering Surgery; Humans; Hydrogen-Ion Concentration; Injections; Intraocular Pressure; Mitomycin
PubMed: 30950967
DOI: 10.1097/IJG.0000000000001257 -
Expert Opinion on Drug Safety Jan 2007Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis. Its use and application in ophthalmology has been increasing in recent years because of... (Review)
Review
Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis. Its use and application in ophthalmology has been increasing in recent years because of its modulatory effects on wound healing. Current applications include pterygium surgery, glaucoma surgery, corneal refractive surgery, cicatricial eye disease, conjunctival neoplasia and allergic eye disease. Although it has been used successfully in these conditions, it has also been associated with significant complications. This article reviews the current trends and uses of mitomycin C in the eye and its reported complications.
Topics: Eye Diseases; Humans; Mitomycin; Ophthalmology
PubMed: 17181449
DOI: 10.1517/14740338.6.1.27 -
Cancer Metastasis Reviews Jun 1993A role of DTD in the bioreductive activation of mitomycin C was supported by indirect evidence utilizing enzyme inhibitors in cellular systems. Using a cell-free system,... (Review)
Review
A role of DTD in the bioreductive activation of mitomycin C was supported by indirect evidence utilizing enzyme inhibitors in cellular systems. Using a cell-free system, we have confirmed that DTD can bioactivate mitomycin C using both purified rat and human DTD. Metabolism and bioactivation of mitomycin C by DTD is pH-dependent. At pH 7.8 alkylation of DTD leading to enzyme inhibition and DTD crosslinking occurs whereas at pH values of 7.4 and below metabolite formation, preservation of catalytic activity of DTD and sequence-selective DNA crosslinking occurs. Bioactivation of mitomycin C by DTD and the cytotoxicity of this drug in DTD-rich cell lines is oxygen-independent. Mitomycin C induces greater DNA crosslinking, even after chemical reduction, at lower pH values. This suggests that if mitomycin C is used in tumors with elevated DTD activity, greater therapeutic activity may be obtained by lowering intratumoral pH. Human NSCLC has elevated DTD activity relative to SCLC and normal lung and may be a target for the development of drugs which can be efficiently bioactivated by DTD. Because of the pH-dependent inactivation of DTD by mitomycin C, however, other drugs which are efficiently metabolized and bioactivated by DTD may be better candidates for the therapy of tumors high in DTD such as NSCLC.
Topics: Animals; Cell Line; Humans; Inactivation, Metabolic; Mitomycin; NAD(P)H Dehydrogenase (Quinone); NADPH-Ferrihemoprotein Reductase; Quinones; Tumor Cells, Cultured
PubMed: 8375023
DOI: 10.1007/BF00689803 -
Current Opinion in Otolaryngology &... Dec 2004Mitomycin C was not used in the field of otolaryngology before 1998. Currently it is commonly used by all pediatric otolaryngologists dealing with airway stenoses.... (Review)
Review
PURPOSE OF REVIEW
Mitomycin C was not used in the field of otolaryngology before 1998. Currently it is commonly used by all pediatric otolaryngologists dealing with airway stenoses. Mitomycin C offers the surgeon a method of modifying healing and diminishing granulation tissue and cicatricial scar.
RECENT FINDINGS
There are numerous animal studies showing the beneficial effect of mitomycin C on wound healing in the airway. The human studies rarely have controls and in many cases are case reports. Human studies typically use dosages commonly used in ophthalmology, which are in the low range in relation to the animal airway studies.
SUMMARY
This article attempts to summarize the available research on mitomycin C, helping the clinical otolaryngologist choose the proper dosage, indications, and frequency of use.
Topics: Animals; Child; Granulation Tissue; Humans; Mitomycin; Nucleic Acid Synthesis Inhibitors; Postoperative Complications; Plastic Surgery Procedures; Respiratory System; Tracheal Stenosis; Wound Healing
PubMed: 15548903
DOI: 10.1097/01.moo.0000146708.64004.2b